By ingredient
Medicines for weight management in Canada
Authorization, marketed status, indication and supply are different questions. This index keeps them apart and links the published studies behind each ingredient.
Every weight-management medicine and closely related product authorized in Canada, grouped by ingredient. One ingredient can be sold under several names, for different conditions, in different presentations, with different regulatory statuses. This page is the map; the product pages and the evidence sections have the detail.
Nothing on this page says a medicine is right for anyone, and nothing here is a dose. A product being authorized in Canada does not mean a pharmacy has it, and does not mean a public plan pays for it.
The seven things this page keeps apart
- Authorized in Canada Health Canada has issued a Notice of Compliance and a DIN.
- Marketed status in the DPD The Drug Product Database says Marketed, Approved, Dormant or Cancelled. Approved is not Marketed.
- Actual pharmacy stock Always unknown on this site. Nothing here says a product is on a shelf.
- Canadian indication and age group What the product monograph authorizes, for whom. A US indication is not a Canadian one.
- Provincial public coverage Whether a public plan pays, under what criteria, from what date.
- Provincial interchangeability Whether a pharmacist may substitute a generic for the brand under that province's rules.
- Private insurance Not researched. Every plan differs.
Semaglutide
Canadian products: Apo-Semaglutide Injection, Aspen-Semaglutide, Ozempic, Plosbrio, Poviztra, Rybelsus, Semaglutide Injection (Aspen), Semaglutide Injection (Dr. Reddy's), Sevmia, Wegovy. 5 marketed, 5 approved but not marketed, on the dates shown on the product page.
Semaglutide in Canada
Product by product: the Canadian indication, the population, the authorized versus marketed status, the presentation and the monograph.
Semaglutide studies explained
20 published studies explained in plain language.
Tirzepatide
Canadian products: Mounjaro and Mounjaro KwikPen, Zepbound. 2 marketed, 0 approved but not marketed, on the dates shown on the product page.
Tirzepatide in Canada
Product by product: the Canadian indication, the population, the authorized versus marketed status, the presentation and the monograph.
Tirzepatide studies explained
9 published studies explained in plain language.
Liraglutide
Canadian products: Saxenda, Victoza. 2 marketed, 0 approved but not marketed, on the dates shown on the product page.
Liraglutide, naltrexone-bupropion and orlistat studies
9 published studies explained in plain language.
No product page yet
This ingredient does not have its own page. The evidence section covers the published studies, and the coverage record shows any public plan listing.
Naltrexone and bupropion
Canadian products: Contrave. 1 marketed, 0 approved but not marketed, on the dates shown on the product page.
Liraglutide, naltrexone-bupropion and orlistat studies
9 published studies explained in plain language.
No product page yet
This ingredient does not have its own page. The evidence section covers the published studies, and the coverage record shows any public plan listing.
Orlistat
Canadian products: Xenical. 1 marketed, 0 approved but not marketed, on the dates shown on the product page.
Liraglutide, naltrexone-bupropion and orlistat studies
9 published studies explained in plain language.
No product page yet
This ingredient does not have its own page. The evidence section covers the published studies, and the coverage record shows any public plan listing.
Setmelanotide
Canadian products: Imcivree. 1 marketed, 0 approved but not marketed, on the dates shown on the product page.
Setmelanotide and rare genetic obesity
2 published studies explained in plain language.
No product page yet
This ingredient does not have its own page. The evidence section covers the published studies, and the coverage record shows any public plan listing.
Orforglipron
Not authorized in Canada. Listed so a reader who has heard the name knows where it stands.
Emerging weight-management medicines
13 published studies explained in plain language.
No product page yet
This ingredient does not have its own page. The evidence section covers the published studies, and the coverage record shows any public plan listing.
Cagrilintide and semaglutide
Not authorized in Canada. Listed so a reader who has heard the name knows where it stands.
Emerging weight-management medicines
13 published studies explained in plain language.
No product page yet
This ingredient does not have its own page. The evidence section covers the published studies, and the coverage record shows any public plan listing.
Retatrutide
Not authorized in Canada. Listed so a reader who has heard the name knows where it stands.
Emerging weight-management medicines
13 published studies explained in plain language.
No product page yet
This ingredient does not have its own page. The evidence section covers the published studies, and the coverage record shows any public plan listing.
Where the rest of the answer lives
- Public drug coverage by province and territory: what each public plan lists, under what criteria, from what date, and how deep the evidence goes.
- The studies behind these medicines: 105 published studies explained in plain language, each linked to the paper.
- Compare documented services: the online and public services that assess and prescribe, with fees as displayed.